McKesson Corp (MCK) Stock Analysis

Verdict: HOLD

Valuation is decoupled from strong fundamental earnings growth; defensive scale provides a floor despite recent executive selling and technical weakness.

Investment score: 64/100

Analysis as of

Is McKesson Corp stock worth reviewing? The TradeMates thesis

McKesson is a defensive powerhouse currently undergoing a technical correction. While executive selling is a yellow flag, the 48.9% earnings growth and dominance in pharma distribution provide a margin of safety at 19.6x earnings.

7-factor investment score

McKesson Corp opportunities and risks

What speaks for MCK

What speaks against MCK

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
MCK20.0x0.2x14.1x3.6%1.2%6.3%
COR21.3x0.2x12.9x3.5%0.8%2.9%
CAH34.3x0.2x19.3x3.7%0.6%8.2%
HSIC23.8x0.7x12.9x29.7%3.0%4.6%
AHCOn/a0.5x7.2x5.4%-2.8%13.9%
ACHn/a0.1x6.0x41.3%-39.8%-84.1%
Peer median21.3x0.2x12.9x5.4%0.6%4.6%

Frequently asked questions about McKesson Corp (MCK)

Is MCK stock a good investment?

The TradeMates model rates McKesson Corp as HOLD with an investment score of 64/100. McKesson is a defensive powerhouse currently undergoing a technical correction. While executive selling is a yellow flag, the 48.9% earnings growth and dominance in pharma distribution provide a margin of safety at 19.6x earnings. This is algorithmic model output, not personal investment advice.

Is MCK stock a buy?

The TradeMates model verdict for MCK is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.